Pathology: la/mBC - HER2 positive - 2nd Line (L2);
| la/mBC - HER2 positive - 2nd Line (L2) | ||||||
| ExteNET, 2016 | NALA (brain metastases), 2020 | NALA, 2020 | HER2CLIMB (patients with brain metastases), 2020 | HER2CLIMB, 2020 | ||
| neratinib plus capecitabine | 2 | T1 | T1 | |||
| tucatinib plus trastuzumab plus capecitabine | 2 | T1 | T1 | |||
| neratinib | 1 | T1 | ||||
| lapatinib plus capecitabine | 0 | T0 | T0 | |||
| trastuzumab plus capecitabine | 0 | T0 | T0 | |||
| placebo | 0 | T0 | ||||